Skip to main content

Table 3 Cases of ROS received pregnancy through different treatments

From: Case report: Birth achieved after effective ovarian stimulation combined with dexamethasone in a patient with resistant ovary syndrome

Author Patient No. Age at intake Type of infertility BMI
(kg/m2)
Basal
AFC
AMH
(μg/L)
Ovarian histology E2 FSH Ig-FSHR Infertility treatments before pregnant Medication/hormonal pretreatment Result
Amos, W. L., Jr. (1985) [12] 1 41 Secondary NA NA NA NA NA 88.4 IU/L NA HRT Estrogens, medroxyprogesterone acetate Liveborn
Jequier, A. M. (1990) [6] 2 28 Secondarya NA NA NA NA 31–52 pmol/L 125 U/L NA HRT 4 cycles (Mestranol + Norethisterone) Liveborn
3 30 Secondarya NA NA NA normal ovarian stroma and follicles 76 pmol/L range seen in postmenopausal women NA HRT Mestranol + Norethisterone Normal pregnancy
Nawroth, F. and R. Sudik (1999) [8] 4 32 Secondary NA NA NA NA NA NA NA HRT 2 mg estradiol valerate and 2 mg estradiol valerate/0.15 mg levonorgestrel Liveborn
Mueller, A., et al. (2003) [9] 5 26 Primary NA NA NA normal density of
follicles
NA 70 IU/L NA HRT 2 mg estradiol valerate and 0.5 mg norgestrel per day administered sequentially Liveborn
Aslam, M. F., et al. (2004) [10] 6 19 Secondary NA NA NA NA NA 133.9 U/L NA HRT 2 mg estradiol valerate and 0.5 mg norgestrel Twice liveborn
7 24 Secondary 27 NA NA NA NA Higher than normal NA HRT estradiol valerate and norgestrel Normal pregnancy
Zielinska, D. and I. Rzepka-Gorska (2011) [11] 8 31 Secondary NA NA NA NA 18.1 pg/ml 58.2 IU/mL NA HRT (spontaneous recovery of ovarian function after HRT) liveborn
Ezeh, U. I. O. and A. J. Breeson (1995) [7] 9 32 22 NA NA NA NA 39 pmol/L 95–115 IU/L NA Ovarian Hyperstimulation eight ampoules of
menotrophin (Pergonal) daily for 14 days
Liveborn
Rogenhofer, N., et al. (2015) [4] 10 26 Secondary 22 15 2.1 NA 28.7 pg/mL 50.8 U/mL antibodies directed to hMG but not to recFSH Controlled Ovarian Hyperstimulation and IVF GnRH analogue
Narfarelin, recombinant follitropin beta, hMG
liveborn
Grynberg, M., et al. (2013) [13] 11 29 primary normal 23 and 18 4.50 and 4.36 NA < 15 40.3 and 38.4 mIU/mL NA IVM 17ß-E2, hCG liveborn
Li, Y., et al. (2016) [14] 12 33 Secondarya NA 25 12.27 NA 260.57 pmol/l 41.99 IU/L NA IVM estradiol valerate, hCG liveborn
Galvao, A., et al. (2018) [15] 13 29 primary 27.7 37 8.6 NA NA 27.7 IU/L NA IVM none liveborn
14 36 primary 18.9 40 2.11 NA NA 7.9 IU/L NA IVM HP-hMG 150 IU/day for 5 days, hCG liveborn
15 23 primary 24.8 50 2.88 NA NA 49.1 IU/L NA IVM 17ß-E2, hCG Twice liveborn
C. Flageole., et al. (2019) [23] 16 31 primary NA 19 3.24 ng/mL NA NA 43–62 IU/L NA IVM hMG (Menopur®) plus rFSH (Gonal F®), hCG liveborn
  1. Abbreviations: BMI body mass index, AFC antral follicle count, AMH anti-müllerian hormone, HRT hormone replacement therapy, IVM in vitro maturation, ART assisted reproductive technologies, rFSH recombinant follicle stimulating hormone, FSHR follicle-stimulating hormone receptor, GnRH gonadotropin-releasing hormone, hCG human chorionic gonadotropin, hMG human menopausal gonadotropin, HP-hMG highly purified human menopausal gonadotropin, 17ß-E2 estradiol-17ß, NA not applicable
  2. aOne live birth after spontaneous birth